An observational study in B-Cell ALL, B-Cell Acute Lymphoblastic Leukaemia and B-Cell Lymphoblastic Leukemia, sponsored by Arkansas Children's Hospital Research Institute. Recruiting at 2 sites in United States. Open to participants aged 1 Year to 23 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Arkansas Children's Hospital Research Institute · Observational
University of South Alabama · Phoenix Children's Hospital · Children's Hospital of The King's Daughters · Staten Island University Hospital · Nemours Children's Hospital · Akron Children's Hospital · Children's Blood and Cancer Center at Dell Children's Medical Center
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:
Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
The most common form of malignancy in children is B-cell acute lymphoblastic leukemia (B-ALL). B-ALL is a type of blood cancer resulting from clonal expansion of an abnormal B-cell precursor known as a lymphoblast. Mature normal B-cells are white blood cells produced in the bone marrow that play a crucial role in fighting infections and in humoral immunity. Abnormal, immature B-cells begin to form and multiply quickly, crowding out healthy cells in the bone marrow. As these cancerous B-cells accumulate, they spill into the bloodstream and can spread (metastasize) throughout the body.
CD19 is the antigen expressed on the surface of nearly all B cells throughout all phases of maturation. CD19 expression plays a crucial role in the body's ability to mount an immune response against a pathogen. Through several studies, CD19 was found to be highly conserved among B-cell malignancies, making it an optimal target for B-ALL treatment. Blinatumomab is a bispecific T-cell engager (BiTE) that links the T-cell CD3 and B-cell CD19. This results in the activation, proliferation, and clonal expansion of T-cells resulting in destruction of the targeted CD19+ cells. Blinatumomab has been shown to improve outcomes among pediatric patients diagnosed with B-ALL significantly; and is now a part of the backbone of treatment for B-ALL.
A key concern for the pediatric population receiving blinatumomab is the potential loss of vaccine-induced immunity established before chemotherapy. Intensive chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) can impair humoral immunity, leading to the loss of antibodies generated by previous vaccinations due to the depletion of memory B cells. Currently, there is no established protocol for revaccination in B-ALL patients treated with blinatumomab. However, prior studies involving other immunotherapeutic agents, such as CAR T-cell therapy, have shown that patients often exhibit low post-treatment antibody titers, necessitating booster doses or even full revaccination. Because blinatumomab has shown to improve outcomes in the vast majority of children with B-ALL, it is critical to determine the unknown long-term effects on humoral immunity in these patients.
Clinical practice regarding revaccination post-chemotherapy in the B-ALL population is widely variable. Children with leukemia who have undergone chemotherapy often experience prolonged immunosuppression, making them particularly vulnerable to vaccine-preventable diseases. The disease itself, combined with its treatment, causes significant immunosuppression-especially in acute lymphoblastic leukemia (ALL)-when compared to solid tumors. While partial immune recovery may occur approximately three months after chemotherapy, full recovery can take longer and depends on factors such as the patient's age, type of cancer, and the intensity of treatment received. In immunocompromised patients, live vaccines are generally considered to be unsafe, putting patients at high risk of viral reactivation. However, non-live (inactivated) vaccines are considered safe and effective. Therefore, it is essential to establish a clear vaccination protocol to protect this vulnerable population from preventable infections.
While standard vaccination practices aim to establish long-term protection against vaccine-preventable diseases, the durability of this immunity following immunotherapy remains unclear. This study will assess whether pediatric patients (less than 21 years old) who have been treated with blinatumomab retain protective antibody titers from their primary childhood vaccinations and whether revaccination restores immune protection. Because the vast majority of B-ALL patients - including B-Lymphoblastic Lymphoma - will receive 2 cycles of blinatumomab during their treatment, understanding the long-term impact of this drug on vaccine-induced humoral immunity is imperative.
The investigators hypothesize that pediatric patients with B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (B-ALL/Ly) who have received blinatumomab will not retain protective immunity conferred by the routine childhood primary series of vaccinations and that revaccination will result in a robust serologic response.
976 studies on the registry are indexed under Burkitt Lymphoma; 159 are open to participants now.
This study's planned enrollment of 300 is above the median of 152 across 66 observational studies indexed under Burkitt Lymphoma.
Browse Burkitt Lymphoma studies →Arkansas Children's Hospital Research Institute is the lead sponsor of 122 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Potential participants will be identified through referrals and from medical records. Prospective participants are those who have been captured prior to starting chemotherapy, and retrospective participants are those who have been captured after starting chemotherapy or have finished chemotherapy within the previous 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who have received blinatumomab
Participants who have not received blinatumomab
Proportion of participants with protective serum antibody titers
Participants will have antibody titers evaluated as standard of care. Titers evaluated include: tetanus, Haemophilus influenzae type b \[Hib\], Hepatitis B, Streptococcus pneumoniae \[pneumococcal\], Varicella Zoster Virus, and Measles
Time frame: >/= 6 months following the completion of blinatumomab therapy
Proportion of participants who achieve seroconversion (i.e., transition from non-protective to protective antibody titers)
Will assess whether revaccination restores protective immunity in participants with non-protective titers after blinatumomab
Time frame: within 6 months following revaccination
Comparison of protective titer rates between Case and Control groups
Comparison of protective titer rates between participants who received blinatumomab and those who did not, adjusting for age, treatment intensity, and time since last vaccine dose
Time frame: >/= 6 months following the completion of therapy
Plan to share: No — Individual participant data will not be shared with other researchers, and each participating site has access to only their center's data; however, aggregated data will be be included in future publications and will be made available to participating centers following study completion.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
University of South Alabama · Phoenix Children's Hospital · Children's Hospital of The King's Daughters · Staten Island University Hospital · Nemours Children's Hospital · Akron Children's Hospital · Children's Blood and Cancer Center at Dell Children's Medical Center
University of South Alabama · Phoenix Children's Hospital · Children's Hospital of The King's Daughters · Staten Island University Hospital · Nemours Children's Hospital · Akron Children's Hospital · Children's Blood and Cancer Center at Dell Children's Medical Center
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arkansas Children's Hospital Research Institute →